HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
First Claim
1. An isolated nucleic acid molecule encoding a recombinant human antibody or antigen-binding fragment thereof that specifically binds human glucagon receptor (hGCGR), wherein the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within any one of the HCVR amino acid sequences selected from the group consisting of SEQ ID NOs:
- 2, 18, 34, 50, 66, 70, 86, 90, 106, 110, 126, 130 and 146; and
the three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within any one of the LCVR amino acid sequences selected from the group consisting of SEQ ID NOs;
10, 26, 42, 58, 68, 78, 88, 98, 108, 118, 128, 138 and 148.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
-
Citations
17 Claims
-
1. An isolated nucleic acid molecule encoding a recombinant human antibody or antigen-binding fragment thereof that specifically binds human glucagon receptor (hGCGR), wherein the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within any one of the HCVR amino acid sequences selected from the group consisting of SEQ ID NOs:
- 2, 18, 34, 50, 66, 70, 86, 90, 106, 110, 126, 130 and 146; and
the three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within any one of the LCVR amino acid sequences selected from the group consisting of SEQ ID NOs;
10, 26, 42, 58, 68, 78, 88, 98, 108, 118, 128, 138 and 148. - View Dependent Claims (6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
- 2, 18, 34, 50, 66, 70, 86, 90, 106, 110, 126, 130 and 146; and
-
2. An isolated nucleic acid molecule encoding a recombinant human antibody or fragment thereof that binds specifically to human GCGR, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NOs:
- 2, 18, 34, 50, 66, 70, 86, 90, 106, 110, 126, 130 and 146.
- View Dependent Claims (3)
-
4. An isolated nucleic acid molecule encoding a recombinant human antibody or fragment thereof that binds specifically to human GCGR, wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region (LCVR) selected from the group consisting of SEQ ID NOs:
- 10, 26, 42, 58, 68, 78, 88, 98, 108, 118, 128, 138 and 148.
- View Dependent Claims (5)
Specification